<DOC>
	<DOCNO>NCT00516750</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate , vinblastine , doxorubicin , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Evaluating blood tissue sample patient cancer may help doctor learn change occur DNA , identify biomarkers related cancer , predict well patient respond combination chemotherapy . PURPOSE : This phase II trial study gene expression profile see well work predict response treatment patient invasive bladder cancer receive methotrexate , vinblastine , doxorubicin , cisplatin .</brief_summary>
	<brief_title>Gene Expression Profiling Patients With Invasive Bladder Cancer Receiving Methotrexate , Vinblastine , Doxorubicin , Cisplatin</brief_title>
	<detailed_description>OBJECTIVES : Primary - Analyze correlation gene expression profile effect chemotherapy detect significant cluster gene useful predict chemosensitivity . - Confirm reduction original tumor size patient invasive bladder cancer treat methotrexate , vinblastine , doxorubicin hydrochloride , cisplatin . Secondary - Determine safety regimen patient . - Determine overall survival rate patient treat regimen . - Assess reduction size metastatic lesion patient treat regimen . OUTLINE : This multicenter study . Patients receive methotrexate day 1 , 15 , 22 , vinblastine day 2 , 15 , 22 , doxorubicin hydrochloride cisplatin day 2 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Patient sample collect gene expression profile . After completion study treatment , patient follow 3 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis invasive bladder cancer Must confirm chest abdominal CT scan OR pelvic MRI scan transurethral biopsy ( definitive muscle invasion &gt; T2 ) within 4 week prior registration PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm^3 Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 1.5 mg/dL Serum creatinine ≤ 1.5 mg/dL AST ALT ≤ 2.5 x upper limit normal Not pregnant No liver cirrhosis No ischemic cardiovascular disease arrhythmia treatment necessary No cardiac infarction within past 6 month No interstitial pneumonia , pulmonary fibrosis , diseases oxygen inhalation therapy need No active cancerous lesion upper urinary tract tumor No high fever infectious symptom No uncontrolled hypertension diabetes mellitus PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
</DOC>